Review Article
The Role of Antioxidant Enzymes in the Ovaries

Shan Wang,1,2 Guolin He,1 Meng Chen,1 Tao Zuo,2 Wenming Xu,2 and Xinghui Liu1

1Department of Obstetrics and Gynecology, West China Second University Hospital, Sichuan University, Chengdu 610041, China
2Joint Laboratory of Reproductive Medicine, Sichuan University-The Chinese University of Hong Kong (SCU-CUHK), West China Second University Hospital, Sichuan University, Chengdu 610041, China

Correspondence should be addressed to Wenming Xu; xuwenming1973@163.com and Xinghui Liu; xinghuiliu@163.com

Received 30 May 2017; Accepted 19 July 2017; Published 24 September 2017

Academic Editor: Rodrigo Franco

Copyright © 2017 Shan Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Proper physiological function of the ovaries is very important for the entire female reproductive system and overall health. Reactive oxygen species (ROS) are generated as by-products during ovarian physiological metabolism, and antioxidants are indicated as factors that can maintain the balance between ROS production and clearance. A disturbance in this balance can induce pathological consequences in oocyte maturation, ovulation, fertilization, implantation, and embryo development, which can ultimately influence pregnancy outcomes. However, our understanding of the molecular and cellular mechanisms underlying these physiological and pathological processes is lacking. This article presents up-to-date findings regarding the effects of antioxidants on the ovaries. An abundance of evidence has confirmed the various significant roles of these antioxidants in the ovaries. Some animal models are discussed in this review to demonstrate the harmful consequences that result from mutation or depletion of antioxidant genes or genes related to antioxidant synthesis. Disruption of antioxidant systems may lead to pathological consequences in women. Antioxidant supplementation is indicated as a possible strategy for treating reproductive disease and infertility by controlling oxidative stress (OS). To confirm this, further investigations are required and more antioxidant therapy in humans has to been performed.

1. Background

Reactive oxygen species (ROS) are formed during normal metabolism of oxygen and are produced as by-products of aerobic metabolism. A certain amount of ROS production is necessary for gene expression [1], cell signalling [2, 3], and redox homeostasis. Scavenging antioxidant systems are indispensable for maintaining an adequate amount of ROS. The balance between the generation and elimination of ROS is a key factor required for almost every metabolic function in mammals. Maintenance of this balance is an important constitutive process and has a particular influence on cell proliferation, differentiation, apoptosis, and death [4]. When ROS production overwhelms the scavenging ability of antioxidants, oxidative stress (OS) occurs. Unfortunately, disruption of this balance can easily result from either an increase in the concentration of ROS or a decrease in scavenging ability. Excessive ROS levels are harmful to the human body and can result in accumulation of oxidative damage in distinct subcellular compartments that exert very toxic effects on DNA, proteins, and lipids. ROS-mediated damage can ultimately influence physiological functions, such as cell signalling pathways and redox-sensitive signalling pathways, and lead to pathological conditions [5].

Regarding the female reproductive system, ROS and antioxidants have been recognized as key factors involved in ovarian physiological metabolism. Many studies have investigated the presence of antioxidants and their transcripts in the female reproductive tract [6–8]. Previous studies have reported that the balance between ROS and antioxidants greatly influences the reproductive activities in female mammalian animals, such as endometrial changes in different luteal phases, folliculogenesis, ovulation, fertilization, placental growth, embryogenesis, and implantation [9]. However, under OS conditions, compromised reproduction and fertility may be induced, including impaired ovarian functions,
deteriorated oocyte quantity, embryonic development disorders, gynaecological disease, and infertility [10–13]. Thus, antioxidants are critical for maintaining the redox balance in the ovaries to support normal ovarian function. However, their exact molecular mechanisms and roles have not been fully elucidated. Previous studies have primarily focused on ROS functions in the ovaries. Thus, in this context, a systematic understanding of antioxidant expression, regulation, and molecular mechanisms involved in ovarian function is required. Reproductive diseases caused by reduced antioxidant system capacity are also described, and for this reason, future investigations of possible antioxidant supplementation to protect against these diseases are necessary.

2. Metabolic Mechanism of ROS and Antioxidants

2.1. Reactive Oxygen Species. Reactive oxygen species include radical species, for example, the superoxide anion radical \( \text{O}_2^- \). Although hydrogen peroxide \( \text{H}_2\text{O}_2 \) does not contain unpaired electrons and is therefore not a radical, it is still considered as a form of ROS. The hydroxyl radical \( \cdot \text{OH} \) is the most highly reactive and toxic form of oxygen [14]. In addition to ROS, reactive nitrogen species (RNS) have similar effects on cells. RNS include radical species, such as primary nitric oxide \( \cdot \text{NO} \) [15].

The redox state of cells is maintained by multiple enzymes and factors. \( \text{O}_2^- \) production is normally the initial step of ROS production and propagation, and thus, \( \text{O}_2^- \) is considered the precursor of other ROS and functions as a regulator in oxidative chain reactions. After \( \text{O}_2^- \) dismutation, \( \text{H}_2\text{O}_2 \), which is relatively stable and able to pass through cell membranes, is formed [16]. In the presence of \( \text{O}_2^- \), \( \text{H}_2\text{O}_2 \) and iron, the Haber-Weiss reaction will occur, which generates \( \cdot \text{OH} \) [17, 18]. In addition, NO and peroxynitrite (ONOO–) are very important radical species in cells. NO is a well-known key factor for many cellular events and acts as an inhibitor for cell apoptosis and death in a wide range of mammalian cells [19–21]. NO is usually generated from L-arginine via NO synthase (NOS) activity [15] in mitochondria because NOS is located in mitochondria [22, 23]. As a reactive nitrogen intermediate, ONOO– exerts pro-oxidant actions more often than NO itself [24].

2.2. Antioxidant Systems. Antioxidant mechanisms exist in all organisms, which enable them to cope with oxidative environments and help cells repair the damage caused by ROS [25]. These mechanisms can be divided into nonenzymatic and enzymatic mechanisms. Enzymatic antioxidants include catalase, SOD, glutathione peroxidase (GPX), glutathione reductase (GR), and glutathione oxidase (GPOX). SOD, catalase, and GPX are the three most common enzymatic antioxidants, and they play critical roles in removing the harmful oxygen products produced by superoxide dismutase [26]. Glutathione (GSH) is considered the major representative of nonenzymatic antioxidants present in oocytes and embryos [27]; other types of nonenzymatic antioxidants include vitamin C, vitamin E, selenium, Zn, carotene, and beta-carotene [28].

The most harmful ROS, \( \text{O}_2^+ \), is removed by SOD in a dismutation reaction, which is considered the initial and first vital step for regulating intracellular \( \text{O}_2^+ \) production. The products of this reaction include molecular oxygen \( \text{O}_2 \) and hydrogen peroxide \( \text{H}_2\text{O}_2 \) [16]. To date, three different widely expressed types of SOD have been recognized in organisms. Cu/Zn-SOD (SOD1) is located in cytoplasm and nuclear compartments, while Mn-SOD (SOD2) is expressed in the mitochondria [29]. SOD1 and SOD2 are dimeric and homotetrameric proteins, respectively. EC-SOD (SOD3) is a tetrameric glycoprotein located in the extracellular space [30, 31]. Following the dismutation reaction, hydrogen peroxide can be catalysed by either GPX or catalase into \( \text{H}_2\text{O} \). GPX is present in both the mitochondria and cytoplasm [32], while catalase is detected only in peroxisomes [33]. After converting \( \text{H}_2\text{O}_2 \) into \( \text{H}_2\text{O} \), reduced GSH is oxidized to GSSG (oxidized glutathione) in a peroxidase reaction. Within cells, GSSG is reduced by NADPH. NADPH then regenerates GSH through the enzymatic activity of GR [33]. This entire process is called "GSH recycling," and it is of fundamental importance for the oxidant scavenging ability of cells. Glutathione transferase (GST) is an enzyme that belongs to a family of multifunctional enzymes. GST plays a vital role in detoxifying reactive metabolites by catalysing their conjugation with GSH. Some of these reactive metabolites are different types of electrophilic alkylation compounds, which are the products generated from OS in macromolecules or biological membranes [34]. GST can transfer the reactive compounds to subcellular sites for further excretion and/or transformation [35]. Figure 1 illustrates a portion of the ROS and antioxidant metabolic pathways. In addition to the endogenous antioxidants mentioned above, vitamins, for example, vitamin C and vitamin E, among other dietary antioxidants, can also directly scavenge ROS with very high efficiency. Through this scavenging activity, vitamin C and vitamin E provide another major source of protection from ROS-induced damage in cells [19, 36, 37]. Trace elements are also vital antioxidants because they can provide an active site in cells necessary for antioxidants to function properly or participate in the regulation of antioxidant enzymes as cofactors [38, 39]. Polyphenols are ubiquitous in a healthy diet, found in fruits and vegetables, and act as "ROS cleaners" or natural antioxidants. Hence, polyphenols are particularly important for the human body [40].

3. A Brief Overview of the Physiological Roles of ROS in the Ovaries

ROS exert both negative and positive effects in mammalian ovaries [41]. From oocyte maturation to fertilization, ROS affect multiple physiological and pathological activities in the ovaries.

Different markers of OS have been examined in cycling ovaries [42, 43]. Macrophages, leukocytes, and cytokines, which are major sources of ROS, are all present in the follicular fluid microenvironment. ROS in the follicular fluid are involved in follicular growth, oocyte maturation, and ovarian steroid biosynthesis [44]. Angiogenesis is a critical process
...for ovarian folliculogenesis, dominant follicle selection, corpus luteum formation, and embryo formation [45, 46]. Angiogenesis is promoted by oestrogens with some cellular factors, such as VEGF [47]. ROS produced from NADP(H) oxidase were reported to be critical for angiogenesis in vivo and VEGF signalling in vitro [48]. Accordingly, ROS are involved in follicular growth in part by regulating angiogenesis. The development of follicles from the primordial stage to antral follicles is accompanied by a marked increase in the metabolic function of granulosa cells, especially a large increase in cytochrome P450 activity with steroid biosynthesis [49]. Large amounts of ROS are produced during electron transport, indicating that functional granulosa cells are related to the pro-oxidant state in the follicles. When the pre-ovulatory follicle is formed, ovulation occurs under luteinizing hormone (LH) stimulation [50]. A certain amount of ROS is required for ovulation [41], and inhibition of ROS has been confirmed to hinder ovulation [41, 51]. In preovulatory follicles, excessive antioxidants impair LH-stimulated progesterone secretion and ovulation-related gene expression [41]. ROS are induced in preovulatory follicles with oscillation of prostaglandins, cytokines, proteolytic enzymes, and steroids, resulting in blood flow alterations and eventual follicle rupture [52]. The ovulation process is compared with an acute inflammatory reaction because many genes and reagents related to inflammation are induced in the preovulatory follicles by the LH surge during ovulation [53, 54].

ROS function as critical modulators during the inflammatory reactions involved in follicular rupture [55]. With the exception of dominant follicles, which are released for fertilization, the other growing follicles will all undergo apoptosis, and this process is promoted by ROS. In parallel, FSH-induced oestrogen synthesis and upregulation of catalase and GSH in growing follicles counteract the apoptotic process to maintain the balance during normal ovarian function [56]. During the luteal phase, a large amount of progesterone is produced to maintain the early stage of pregnancy. If pregnancy does not occur, the corpus luteum regresses [56]. A rapid reduction in progesterone is required for adequate follicular maturation in the next reproductive cycle. ROS are generated in the corpus luteum and are involved in functional luteolysis. ROS and antioxidants are related to progesterone synthesis in the luteal phase [27]. Steroidogenesis is a major source of ROS production, and progesterone synthesis is restricted in the corpus luteum with ROS [57]. During pregnancy, decreased SOD1 induces an increase in ROS production, resulting in progesterone inhibition, and thus, scavenging of ROS by antioxidants may contribute to the maintenance of luteal cell integrity and extend the life span of the corpus luteum [58].

4. Antioxidants in the Ovaries

As described in Background, as the defence system for maintaining the redox balance under physiological conditions, antioxidants have a large influence on reproductive activities [9]. Historically, scientists have emphasized the function of ROS in female reproduction rather than that of antioxidants, and most papers are related to reproductive activities that occur after ovulation, while the follicular growth process is rarely discussed. Thus, we have reviewed antioxidants and their relative roles in almost all ovarian activities. Among all the antioxidants, we chose to discuss the most significant antioxidants, including catalase and SOD, and the antioxidants involved in GSH recycling. Their regulation during the ovarian cycle and follicular maturation are systematically reviewed. In addition, relevant literature is listed and discussed with regard to the roles of antioxidants in oocyte maturation, ovulation, corpus luteum function, and steroidogenesis. The possible regulatory function of gonadotropins on antioxidants is also addressed here.

4.1. Catalase. Catalase plays a critical role in ROS metabolism. For this reason, catalase has been intensely studied in...
recent years. However, very limited evidence has been found regarding catalase regulation in follicular development and differentiation. Catalase is predominantly found in peroxisomes. In the ovaries, catalase was first detected in 1975 by immunohistochemistry [59]. Catalase expression in oocytes is low compared with other cell types in the follicles [60, 61]. In the oocyte nucleus, chromosomal defects such as chromosome misalignment and DNA damage can be induced after inhibition of catalase, and during meiotic maturation in mouse oocytes, catalase has been shown to protect the genome from oxidative damage [60].

Regarding catalase regulation in follicular growth, the activity of catalase in granulosa cells from large follicles has been observed to be several times higher than that in small and medium follicles in various mammals, such as pigs [62], goats [63], and rats [64]. In rat ovarian granulosa and theca cells, increased catalase activity can be observed during ovarian development and luteinisation [65, 66]. Except in folliculogenesis, catalase content has also been found to be distributed throughout different oestrous phases. Singh and Pandey observed that catalase activity in total ovary homogenate was highest in the metestrus phase, declined in the oestrus and pro-oestrous stages, and reached the lowest levels in the diestrus phase [67]. Nevertheless, catalase concentration in follicular fluid is not significantly different among follicles of different sizes [68, 69].

The distribution and oscillation of catalase during different ovarian cycles are suggested to be related to gonadotropin regulation. Gonadotropins such as FSH have well-known functions that are primarily important for follicular maturation, differentiation, and steroidogenesis [70]. Interestingly, catalase activity has been reported to be significantly enhanced through gonadotropin stimulation in different mammals [63, 71–73]. Behl and Pandey further investigated whether catalase and oestriadiol activities in ovarian granulosa cells in different follicle stages were related to FSH levels. They found that not only oestriadiol secretion but also catalase activity increased after FSH stimulation, and the degree of this increase was greater in large follicles than in medium or small follicles [63]. As it is well known that oestrogen reaches its highest concentration in dominant follicles, the concomitant increase in catalase and oestriadiol in response to FSH may suggest a role of catalase in follicle selection and prevention of apoptosis. After ovulation was blocked, catalase activity increases significantly in the entire follicle as well as in the thecal cells [64]. Furthermore, the activity of catalase in both rat and pig ovaries has been shown to be positively correlated with the amount of ferredoxin and cytochrome P450scc, which are two constituents of the steroidogenic electron transport chain [74]. In steroidogenic biogenesis, oxygen free radicals such as superoxide are produced [75–78] and then catalysed by SOD to H$_2$O$_2$ [16, 79]. Accordingly, catalase acts as a protective factor to neutralize H$_2$O$_2$ to maintain ROS balance and normal steroid levels. These studies show that catalase contributes to follicular development, the oestrous cycle, and steroidogenic events in the ovaries.

4.2. SOD. SOD enzyme families are present in multiple tissues and ovaries of different mammals. The location of SOD in the human body was first determined by Shiotani et al. [80] and Tamate et al. [43] using immunohistochemistry. Neither SOD1 nor SOD2 has been observed in primordial and primary follicles. SOD2 has been detected in secondary follicles, while SOD1 begins to appear in theca cells after the formation of the antral cavity. SOD1 cannot be detected in granulosa cells until follicles enter the dominant follicle stage. High expression levels of both SOD1 and SOD2 have been detected in luteinized granulosa and theca cells.

Biochemically, a peak of collective SOD activity appears during the pro-oestrus phase, which involves the lowest level of superoxide radicals compared with other oestrous stages [81, 82]. Both the amount and activity of the three SOD isoforms in follicular fluid are greater in small and medium follicles than in large antral follicles, and these findings have been assessed and verified in different animals [68, 69, 83, 84]. Interestingly, compared with follicular fluid, no changes in SOD have been observed in granulosa cells with regard to the size of the follicles [83]. Furthermore, high SOD activity in follicular fluid was correlated with low fertilization rates in humans by comparing SOD activity in follicular fluid from patients whose oocytes did not become fertilized with those whose oocytes did become fertilized [85]. According to the above evidence, relatively decreased SOD activity in large follicular fluid is necessary to ensure that ROS levels reach a threshold value that is required for ovulation. However, excessive ROS production in preovulatory follicles may exert harmful effects to oocytes. An oocyte in the preovulatory follicle acquires developmental competence and a very active metabolism, and during this process, a large amount of ROS can be generated; thus, SOD1 is required to neutralize O$_2^•$ in the cytoplasm of oocytes [86], and therefore, SOD must be maintained at a certain concentration and activity level within the follicles to guarantee a balance between O$_2^•$ and H$_2$O$_2$ for normal cellular function [87]. Conclusively, a certain amount of SOD not only ensures a functional concentration of ROS for ovulation but also protects oocytes from OS. After ovulation, SODs are very active in the corpus luteum, because corpus luteum function is related to progesterone levels and ROS. Interestingly, progesterone fluctuation in the luteal phase is positively correlated with SOD1 activity. Reduction in SOD1 during corpus luteum regression is accompanied by increased ROS levels. In contrast to SOD1, SOD2 concentration in the corpus luteum is enhanced in the regression phase to clear the excess ROS produced in mitochondria by cytokines and inflammatory reactions. Thus, SOD1 activity in the corpus luteum is closely correlated with progesterone secretion, while SOD2 is primarily targeted to protect the luteal cells from oxidative damage caused by inflammation [27].

Successful cultivation of cumulus cell-oocyte complexes (COCs) in vitro has made it possible to analyse the function of the SOD isoforms in oocytes. SOD1 and SOD3 are expressed in the oocyte nucleus, and SOD3 is the only SOD isform that can be detected in the zona pellucida. The level of SOD1 in the oocyte nucleus is enhanced in small and medium-sized follicles [83]. Interestingly, SOD3 can be
translocated from cumulus cells into oocytes under certain conditions [88]. This evidence may demonstrate that SOD1 and SOD3 potentially contribute to the protection of DNA or transcription regulation of redox-sensitive genes. Mammalian oocytes contain many a large number of mitochondria, and SOD2, which is specifically localized to the mitochondria and is the principle scavenger of mitochondrial superoxide [89, 90]. The extracellular matrix, which is an important component of COCs, is dynamically regulated, and SOD3 was shown to be one of the critical regulators [91]. When ovulation occurs, there is a surge in ROS production in COCs, and OS is greatly enhanced [44]. Consequently, COCs may stockpile the various SOD isofoms for upcoming events, such as ovulation, fertilization, and early embryonic development.

Matzuk et al. generated SOD1 null mice with reduced fertility as evidenced by a decreased number of preovulatory follicles and corpora lutea; primary and small antral follicles but few corpora lutea were found in these mice under histological analysis [92]. Another group created a copper chaperone for superoxide dismutase (CCS)-null mice that induced marked reductions in SOD1 activity. CCS (+/-) mice showed abnormal development of the antral follicles and no corpus luteum [93]. Furthermore, SOD1 is reportedly involved in antral follicle development. Matzuk et al. also examined SOD2-deficient mice, and they found that SOD2-deficient mice die within three weeks of birth. After the authors completed transplantation of oocytes from the postnatal SOD2-deficient mice to bursa wild-type hosts, all follicle stages were detected, and viable oocytes during the luteal phase [96]. Kawaguchi et al. found that LH can increase the alpha-class GST expression levels were much higher in the pro-oestrus phase than in the diestrus phase in total ovary homogenates [104]. These results suggest that different enzymes involved in GSH recycling are sensitive to the changes that occur during the oestrous cycle, with different regulation mechanisms and various effects among different follicle sizes. However, the regulatory mechanism of these antioxidants during the ovarian cycle and follicular growth is poorly characterized.

According to the literature, GSH increases gamete viability and fertilization. GSH content was reported to be decreased by approximately 10-fold in unfertilized mouse oocytes [105]. In addition, researchers have described GSH contribution to spindle formation in bovine oocytes via depletion of GSH in oocytes; after GSH depletion, the spindle poles became wider, and the spindle area increased significantly [106]. Furthermore, high GSH content in oocytes during follicular development is related to improved development competence of the follicle [107–109]. In addition to GSH, GPX has been reported to play significant roles in gametogenesis and in vitro fertilization. The activity of GPX in the follicular fluid of follicles that were subsequently fertilized was higher than that in fluid from nonfertilized follicles [110]. During the GSH cycle, GR, which cycles GSSG back to GSH, may also play a pivotal role in ovarian function by maintaining GSH at reduced levels [102].

Both in vivo and in vitro studies have shown that the oocyte GSH concentration is modulated by gonadotropin signalling during the preovulatory period. In vivo studies revealed that FSH stimulation enhanced ovarian GSH content [103, 111]. In addition, the GSH content in cumulus cells was gradually increased during oocyte maturation in pigs [112, 113], cattle [114], and horses [115]. One research group has shown that GSH content was increased in porcine oocytes and cumulus cells under FSH treatment in pigs via modulation of glutamate cysteine ligase (GCL) subunit mRNA [116]. GCL is the rate-limiting enzyme in GSH synthesis. In contrast, another research group observed a reduction in GSH and transcript levels encoding GSH in the presence of FSH alone in COCs of cattle [117], but this

4.3. GSH Recycling. GSH is a low molecular weight thiol that is predominantly expressed in mammalian cells. GSH maintains cells in a reduced state and functions as an electron donor for some antioxidant enzymes [99, 100]. GSH is involved in many cellular functions, including cell proliferation, differentiation, and apoptosis [101]. GSH can be synthesized de novo from glutamate, cysteine, and glycine via catalysis by glutamate cysteine ligase and glutathione synthetase. Another predominant enzymatic system for maintaining GSH in most tissues is the reduction of GSSG to GSH via GR with NADPH consumption [99]. GSH can then be oxidized back to GSSG. In the ovary, the strongest GR activity is found in oocytes [102].

Studies of ovarian functions have demonstrated that the GSH concentration in follicular fluid in large follicles is significantly higher than that in small follicles during the luteal phase [68]. Luderer et al. reported that the GSH content in the oocytes increased from the oestrous to metestrus phase compared with the diestrus to pro-oestrus phase in adult rats [103]. Accordingly, the highest GR activity was detected in the metestrus phase [102]. Surprisingly, Lee et al. discovered that ovarian alpha-class GST expression levels were much higher in the pro-oestrus phase than in the diestrus phase in total ovary homogenates [104]. These results suggest that different enzymes involved in GSH recycling are sensitive to the changes that occur during the oestrous cycle, with different regulation mechanisms and various effects among different follicle sizes. However, the regulatory mechanism of these antioxidants during the ovarian cycle and follicular growth is poorly characterized.

According to the literature, GSH increases gamete viability and fertilization. GSH content was reported to be decreased by approximately 10-fold in unfertilized mouse oocytes [105]. In addition, researchers have described GSH contribution to spindle formation in bovine oocytes via depletion of GSH in oocytes; after GSH depletion, the spindle poles became wider, and the spindle area increased significantly [106]. Furthermore, high GSH content in oocytes during follicular development is related to improved development competence of the follicle [107–109]. In addition to GSH, GPX has been reported to play significant roles in gametogenesis and in vitro fertilization. The activity of GPX in the follicular fluid of follicles that were subsequently fertilized was higher than that in fluid from nonfertilized follicles [110]. During the GSH cycle, GR, which cycles GSSG back to GSH, may also play a pivotal role in ovarian function by maintaining GSH at reduced levels [102].

Both in vivo and in vitro studies have shown that the oocyte GSH concentration is modulated by gonadotropin signalling during the preovulatory period. In vivo studies revealed that FSH stimulation enhanced ovarian GSH content [103, 111]. In addition, the GSH content in cumulus cells was gradually increased during oocyte maturation in pigs [112, 113], cattle [114], and horses [115]. One research group has shown that GSH content was increased in porcine oocytes and cumulus cells under FSH treatment in pigs via modulation of glutamate cysteine ligase (GCL) subunit mRNA [116]. GCL is the rate-limiting enzyme in GSH synthesis. In contrast, another research group observed a reduction in GSH and transcript levels encoding GSH in the presence of FSH alone in COCs of cattle [117], but this
phenomenon was rescued by combined treatment with bone morphogenetic protein 15 (BMP15) [117], which is an important factor in ovarian maturation [118, 119]. FSH and BMP15 cotreatment promoted development competence in oocytes by distributing metabolism equally throughout the oocyte. FSH promoted glucose metabolism, while BMP15 accelerated glutathione recycling to protect against cellular OS via increased NADPH production [117].

Gene knock-out mice were created to analyse gene function in the ovaries and during fertilization. Ho et al. created Gpx1-null mice and observed that the mice exhibited normal fertility [120]. Deletion of the entire Gpx4 gene can lead to embryonic death [121]. In comparison, deletion of the mitochondrial form [122] or nuclear form [123] has no effect on female fertility. The fertility of mice with an inactivating mutation in the GR gene was also unaffected [124–126]. Nonetheless, these studies did not investigate the effect of these mutations and deletions on ovarian function. C-Glutamyl transpeptidase 1 (Ggt1) is an enzyme that participates in glutathione synthesis. Ggt1-null mice demonstrated growth retardation and a severe female reproductive phenotype, which included no large antral follicles or corpus luteum in the ovaries and a lack of response of the follicles to exogenous gonadotropin stimulation. All female Ggt1-null mice were completely infertile [127–129], but GSH concentrations were not significantly altered in these mice compared with wild-type mice. Consistent with the Ggt1 mutant phenotype, high-performance liquid chromatography (HPLC) analysis of adult ovaries showed that the intracellular cysteine levels were largely reduced, but interestingly, the female reproductive phenotype was completely rescued by cysteine replacement [127].

GCL is composed of a modifier (GCLM) and a catalytic (GCLC) subunit. GCLM-null mice can survive and reproduce, whereas GCLC-null mice die at the early embryonic stage [130–133]. Oocyte GSH concentrations in GCLM-null mice were less than 20% than those in oocytes of GCLM wild-type mice. Additionally, fertility was markedly reduced due to decreased progression to both the pronucleus and blastocyst stages [134].

ROS are believed to be involved in the initiation of apoptosis, as ROS levels increase prior to any other indicator of apoptosis in follicles. After blocking the synthesis of GSH with the inhibitor buthionine sulfoximine (BSO), a statistically significant increase in atretic antral follicles was observed in rat ovaries [135]. Prevention of apoptosis initiation in antral follicles by FSH is commonly accepted [136, 137]. Interestingly, FSH treatment can reportedly stimulate GSH synthesis [138, 139]. The antiapoptotic effect of FSH on granulosa cell apoptosis can be markedly inhibited by blocking the synthesis of GSH with BSO in cultured follicles [138]. In addition to GSH, catalase and SODs can also protect against apoptosis in large antral follicles in rats [140].

5. Disturbance of Redox State under Pathological Conditions and Ageing

Many physiological processes can be influenced by OS, which can lead to negative effects or even cause pathological conditions in reproductive systems [10–13, 141]. One explanation for these pathological conditions may be, at least in part, decreased scavenging capability of antioxidants, which can lead to excessive ROS production. It has been suggested that the pathological consequences of decreased antioxidant defence systems include many reproductive diseases, such as polycystic ovarian syndrome (PCOS), endometriosis, and unexplained infertility, as well as complications during pregnancy, such as early miscarriage, abortion, recurrent pregnancy loss, and preeclampsia. Age-related fertility decline is also reported to be related to decreased antioxidant systems [8, 142–148].

PCOS is one of the most common gynaecological diseases of reproductive-aged women. Clinical manifestations of PCOS include menstrual disorders or skin disorders and reduced fertilization rate. PCOS is characterized by ovulation dysfunction, hyperandrogenism, and polycystic ovaries [149]. Mitochondrial dysfunction, accompanied by decreased GSH levels and O2 consumption, is found in PCOS patients [150]. Insulin resistance is considered the major aetiology of PCOS. Studies have indicated that antioxidants, including SOD, vitamin C, and vitamin E, are reduced in PCOS patients, leading to an oxidative status that may further cause an inflammatory environment, insulin resistance, and an increase in androgens [151, 152].

Infertility is a disease that is defined as failure to achieve a clinical pregnancy after 12 months or more of regular unprotected sexual intercourse [153]. If the couple has been confirmed infertile without a known cause of infertility after examination, a diagnosis of unexplained infertility is assigned [154]. Approximately 15% of couples are affected by unexplained infertility. Although the pathophysiology is still unclear, evidence has indicated that increased ROS and decreased antioxidants may contribute to unexplained infertility [155–157]. A reduction in antioxidants, including GSH and vitamin E, was reported in patients with idiopathic infertility [158]. Excessive ROS production caused by pathological conditions, environmental changes, or drug therapy may overwhelm antioxidant defence ability and lead to the deterioration of oocyte quality by inducing apoptosis [87, 159–161]. Evidence has further confirmed that ROS-induced granulosa cell degeneration leads to decreased oestrogen levels and compromised oocyte quality and ovulation rate [162]. Chaube et al. revealed that nutrition and growth factors for follicular maturation were affected when granulosa-oocyte communication was reduced under OS, which led to impaired quality of preovulatory follicles [163]. Even after fertilization, excessive ROS production may lead to implantation failure, embryo fragmentation, impaired placentation, and abortion [164]. During pregnancy, the endometrium contributes to the support of embryo development, and this process may be prevented by ROS overproduction [165]. The corpus luteum is critical for maintaining pregnancy in the early stage, and OS may accelerate luteal regression and inhibit steroid production by the corpus luteum [12].

With an increase in reproductive age, the antioxidant levels within the follicular fluid may gradually diminish. Human studies have shown that the levels of catalase and SOD in the follicular fluid of older women were lower than
those in younger women, and older women exhibited lower fertilization rates and reduced blastocyst development [166]. Lim et al. showed that the mRNA levels of mitochondrial antioxidants Prdx3 and Txn2 and cytosolic antioxidants Glrx1 and Gstm2 in mouse ovaries were decreased with increased age, which may influence age-related oxidative damage on ovarian function [167]. Thus, we conclude that the ROS scavenging ability of antioxidants is related to fertilization outcomes.

6. Possible Antioxidant Therapy against ROS

Antioxidants are helpful for minimizing OS induced by excessive ROS production by clearing free radicals and lowering ROS levels in the human body [13]. Both enzymatic and nonenzymatic antioxidants can be useful for overcoming OS caused by ROS [13]. Antioxidant supplementation has been confirmed to have positive effects on mouse oocyte quality by reducing the harmful effects of OS [168]. Melatonin has frequently been investigated in recent years. Animal studies have shown that melatonin was able to prevent OS-mediated deterioration of oocyte quality in rats [161, 169]. Additionally, melatonin contributes to improved reproductive outcomes by enhancing oocyte quality in humans [170, 171]. Thus, melatonin is a very important naturally produced antioxidant in mammals. In addition to melatonin, resveratrol was shown to protect against the reduction of fertility with reproductive ageing in mice by enhancing the number and quality of oocytes [172]. Studies have shown that women with endometriosis intake lower daily amounts of vitamins A, C [173], and E [173, 174] than other women. Daily supplementation with vitamins C and E for four months was found to reduce the OD marker in those patients. However, it did not improve the fertilization rate [174]. N-Acetyl-cysteine (NAC) has antioxidant properties, as it is able to increase intracellular GSH concentrations and/or directly scavenge free radicals [175, 176]. The pregnancy outcomes of patients with unexplained recurrent
products that contain high levels of antioxidants may be beneficial for reducing OS [182].

7. Conclusion

Recently, there has been growing interest in the role of antioxidants in female reproductive activities. Antioxidant products and ROS balance have been shown to be closely related to female subfertility or infertility. Substantial evidence has indicated that some physiological processes, from oocyte maturation to fertilization and embryo development, are particularly sensitive to OS. These processes require antioxidants for balanced function. In this review, we thoroughly discussed the expression and regulation of some major antioxidants involved in follicular development, oocyte maturation, ovulation, corpus luteum function, steroidogenesis, and fertilization. Among these reproductive activities, follicular growth, which is reviewed here, has been previously poorly addressed. The general regulation of antioxidants in follicular development is illustrated in Figure 2. However, the molecular mechanisms behind follicular development have not been fully elucidated, and additional evidence for the role of antioxidants in primordial and primary follicles is needed.

The gynaecological diseases presented in this review may result from changes in early ovarian stages due to dysfunction of antioxidant systems. Thus, it is necessary to emphasize the role of antioxidants in the development and survival process of follicles and in follicle responsiveness to gonadotropins as well as in steroidogenesis. Elucidation of the molecular mechanism underlying the involvement of antioxidants in follicular growth, ovarian cycle, oocyte maturation, and ovulation is essential for creating a better understanding of the possible protective effects of antioxidants and for potentially treating female infertility with antioxidant supplementation in vivo.

Conflicts of Interest

The authors declare that there is no conflict of interest regarding the publication of this paper.

References

[1] R. G. Allen and M. Tresini, “Oxidative stress and gene regulation,” Free Radical Biology & Medicine, vol. 28, pp. 463–499, 2000.
[2] A. U. Khan and T. Wilson, “ Reactive oxygen species as cellular messengers,” Chemistry & Biology, vol. 2, pp. 437–445, 1995.
[3] T. Finkel, “ Oxygen radicals and signaling,” Current Opinion in Cell Biology, vol. 10, pp. 248–253, 1998.
[4] M. Valko, D. Leibfritz, J. Moncol, M. T. Cronin, M. Mazur, and J. Telser, “ Free radicals and antioxidants in normal physiological functions and human disease,” The International Journal of Biochemistry & Cell Biology, vol. 39, pp. 44–84, 2007.
[5] B. Halliwell, “ Tell me about free radicals, doctor: a review,” Journal of the Royal Society of Medicine, vol. 82, pp. 747–752, 1989.
[6] H. Kato, N. Sugino, S. Takiguchi, S. Kashida, and Y. Nakamura, “ Roles of reactive oxygen species in the regulation of luteal function,” Reviews of Reproduction, vol. 2, pp. 81–83, 1997.
[7] N. Sugino, “ Reactive oxygen species in ovarian physiology,” Reproductive Medicine and Biology, vol. 4, pp. 31–44, 2005.
[8] A. Agarwal, S. Gupta, L. Sekhon, and R. Shah, “ Redox considerations in female reproductive function and assisted reproduction: from molecular mechanisms to health implications,” Antioxidants & Redox Signaling, vol. 10, pp. 1375–1403, 2008.
[9] K. H. Al-Gubory, P. A. Fowler, and C. Garrel, “ The roles of cellular reactive oxygen species, oxidative stress and antioxidants in pregnancy outcomes,” The International Journal of Biochemistry & Cell Biology, vol. 42, pp. 1634–1650, 2010.
[10] A. Agarwal, S. Gupta, and S. Sikka, “ The role of free radicals and antioxidants in reproduction,” Current Opinion in Obstetrics & Gynecology, vol. 18, pp. 325–332, 2006.
[11] J. Avila, R. Gonzalez-Fernandez, D. Rotoli, J. Hernandez, and A. Palumbo, “ Oxidative stress in granulosa-lutein cells from in vitro fertilization patients,” Reproductive Sciences, vol. 23, pp. 1656–1661, 2016.
[12] A. Agarwal and S. S. Allamaneni, “ Role of free radicals in female reproductive diseases and assisted reproduction,” Reproductive Biomedicine Online, vol. 9, pp. 338–347, 2004.
[13] A. Agarwal, A. Aponte-Mellado, B. J. Premkumar, A. Shaman, and S. Gupta, “ The effects of oxidative stress on female reproduction: a review,” Reproductive Biology and Endocrinology, vol. 10, p. 49, 2012.
[14] B. Halliwell, “ Protection against tissue damage in vivo by desferrioxamine: what is its mechanism of action?” Free Radical Biology & Medicine, vol. 7, pp. 645–651, 1989.
[15] S. Moncada, R. M. Palmer, and E. A. Higgs, “ Nitric oxide: physiology, pathophysiology, and pharmacology,” Pharmacological Reviews, vol. 43, pp. 109–142, 1991.
[16] J. M. McCord, B. B. Keele Jr., and I. Fridovich, “ An enzyme-based theory of obligate anaerobiosis: the physiological function of superoxide dismutase,” Proceedings of the National Academy of Sciences of the United States of America, vol. 68, pp. 1024–1027, 1971.
[17] B. Halliwell, “ Superoxide-dependent formation of hydroxyl radicals in the presence of iron salts. Its role in degradation of hyaluronic acid by a superoxide-generating system,” FEBS Letters, vol. 96, pp. 238–242, 1978.
[18] J. P. Kehrer, “ The Haber-Weiss reaction and mechanisms of toxicity,” Toxicology, vol. 149, pp. 43–50, 2000.
[19] S. J. Yoon, K. H. Choi, and K. A. Lee, “ Nitric oxide-mediated inhibition of follicular apoptosis is associated with HSP70 induction and Bax suppression,” Molecular Reproduction and Development, vol. 61, pp. 504–510, 2002.
Oxidative Medicine and Cellular Longevity

[20] B. C. Lee, S. H. Kim, and S. Y. Moon, “The role of nitric oxide on apoptosis in human luteinized granulosa cells. Immunocytochemical evidence,” Gynecologic and Obstetric Investigation, vol. 56, pp. 143–147, 2003.

[21] S. Preuthiphan, S. H. Chen, J. L. Tilly, K. Kugu, R. R. Lear, and A. M. Dharmarajan, “Inhibition of nitric oxide synthesis potentiates apoptosis in the rabbit corpus luteum,” Reproductive Biomedicine Online, vol. 9, pp. 264–270, 2004.

[22] P. Ghafourifar and C. Richter, “Nitric oxide synthase activity in mitochondria,” FEBS Letters, vol. 418, pp. 291–296, 1997.

[23] C. Giuli, “Functional implications of nitric oxide produced by mitochondria in mitochondrial metabolism,” The Biochemical Journal, vol. 332, Part 3, pp. 673–679, 1998.

[24] W. H. Koppenol, J. J. Moreno, W. A. Pryor, H. Ischiropoulos, and J. S. Beckman, “Peroxynitrite, a cloaked oxidant formed by nitric oxide and superoxide,” Chemical Research in Toxicology, vol. 5, pp. 834–842, 1992.

[25] C. Michiels, M. Raes, O. Toussaint, and J. Remacle, “Importance of S-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative stress,” Free Radical Biology & Medicine, vol. 17, pp. 235–248, 1994.

[26] I. Fridovich, “Superoxide radical and superoxide dismutases,” Annual Review of Biochemistry, vol. 64, pp. 97–112, 1995.

[27] H. R. Behrmann, P. H. Kodaman, S. L. Preston, and S. Gao, “Oxidative stress and the ovary,” Journal of the Society for Gynecologic Investigation, vol. 8, pp. S40–S42, 2001.

[28] R. Sharma and A. Agarwal, “Role of reactive oxygen species in gynecologic diseases,” Reproductive Medicine and Biology, vol. 3, pp. 177–199, 2004.

[29] R. A. Weisiger and I. Fridovich, “Mitochondrial superoxide dismutase, site of synthesis and intramitochondrial localization,” The Journal of Biological Chemistry, vol. 248, pp. 4793–4796, 1973.

[30] S. L. Marklund, “Human copper-containing superoxide dismutase of high molecular weight,” Proceedings of the National Academy of Sciences of the United States of America, vol. 79, pp. 7634–7638, 1982.

[31] S. L. Marklund, E. Holme, and L. Hellner, “Superoxide dismutase in extracellular fluids,” Clinica Chimica Acta, vol. 126, pp. 41–51, 1982.

[32] G. C. Mills, “Hemoglobin catabolism. I. Glutathione peroxidase, an erythrocyte enzyme which protects hemoglobin from oxidative breakdown,” The Journal of Biological Chemistry, vol. 229, pp. 189–197, 1957.

[33] B. Chance, H. Sies, and A. Boveris, “Hydroperoxide metabolism in mammalian organs,” Physiological Reviews, vol. 59, pp. 527–605, 1979.

[34] J. D. Hayes and L. I. McLeLLan, “Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress,” Free Radical Research, vol. 31, pp. 273–300, 1999.

[35] N. Kaplowitz, “Physiological significance of glutathione S-transferases,” The American Journal of Physiology, vol. 239, pp. G439–G444, 1980.

[36] H. Sies and W. Stahl, “Vitamins E and C, beta-carotene, and other carotenoids as antioxidants,” The American Journal of Clinical Nutrition, vol. 62, pp. 1315S–1321S, 1995.

[37] C. L. Rock, R. A. Jacob, and P. E. Bowen, “Update on the biological characteristics of the antioxidant micronutrients: vitamin C, vitamin E, and the carotenoids,” Journal of the American Dietetic Association, vol. 96, pp. 693–702, 1996.

[38] W. J. Bettinger, “Zinc and selenium, site-specific versus general antioxidation,” Canadian Journal of Physiology and Pharmacology, vol. 71, pp. 721–724, 1993.

[39] S. I. Dashl, M. Thomson, and M. S. Mameesh, “Effects of copper deficiency and Cu complexes on superoxide dismutase in rats,” Nutrition, vol. 11, pp. 564–567, 1995.

[40] A. Scalbert, I. T. Johnson, and M. Saltmarsh, “Polyphenols: antioxidants and beyond," The American Journal of Clinical Nutrition, vol. 81, pp. 215S–217S, 2005.

[41] K. Shkolnik, A. Tadmor, S. Ben-Dor, N. Nevo, D. Galiani, and N. Dekel, “Reactive oxygen species are indispensable in ovulation,” Proceedings of the National Academy of Sciences of the United States of America, vol. 108, pp. 1462–1467, 2011.

[42] T. Suzuki, N. Sugino, T. Fukaya et al., “Superoxide dismutase in normal cycling human ovaries: immunohistochemical localization and characterization,” Fertility and Sterility, vol. 72, pp. 720–726, 1999.

[43] K. Tamate, K. Sengoku, and M. Ishikawa, “The role of superoxide dismutase in the human ovary and fallopian tube,” Journal of Obstetrics and Gynaecology (Tokyo, Japan), vol. 21, pp. 401–409, 1995.

[44] J. Fuji, Y. Iuchi, and F. Okada, “Fundamental roles of reactive oxygen species and protective mechanisms in the female reproductive system,” Reproductive Biology and Endocrinology, vol. 3, p. 43, 2005.

[45] E. Geva and R. B. Jaffe, “Role of angioptin in regulatory tract angiogenesis,” Obstetrical & Gynecological Survey, vol. 55, pp. 511–519, 2000.

[46] J. D. Gordon, S. Mesiano, C. J. Zaloudek, and R. B. Jaffe, “Vascular endothelial growth factor localization in human ovary and fallopian tubes: possible role in reproductive function and ovarian cyst formation,” The Journal of Clinical Endocrinology and Metabolism, vol. 81, pp. 353–359, 1996.

[47] E. D. Albrecht, J. S. Babischkin, Y. Lidor, L. D. Anderson, L. C. Udoff, and G. J. Pepe, “Effect of estrogen on angiogenesis in co-cultures of human endometrial cells and microvascular endothelial cells,” Human Reproduction, vol. 18, pp. 2039–2047, 2003.

[48] M. Ushio-Fukai and R. W. Alexander, “Reactive oxygen species as mediators of angiogenesis signaling: role of NAD(P)H oxidase,” Molecular and Cellular Biochemistry, vol. 264, pp. 85–97, 2004.

[49] J. S. Richards, “Hormonal control of gene expression in the ovary,” Endocrine Reviews, vol. 15, pp. 725–751, 1994.

[50] A. Gougeon, “Human ovarian follicular development: from activation of resting follicles to preovulatory maturation,” Annales d'endocrinologie, vol. 71, pp. 132–143, 2010.

[51] T. Miyazaki, K. Sueoka, A. M. Dharmarajan, S. J. Atlas, G. B. Bulkley, and E. E. Wallach, “Effect of inhibition of oxygen free radical on ovulation and progesterone production by the in-vitro perfused rabbit ovary,” Journal of Reproduction and Fertility, vol. 91, pp. 207–212, 1991.

[52] B. Du, K. Takahashi, G. M. Ishida, K. Nakahara, H. Saito, and H. Kurachi, “Usefulness of intraovarian artery pulsatility and resistance indices measurement on the day of follicle aspiration for the assessment of oocyte quality,” Fertility and Sterility, vol. 85, pp. 366–370, 2006.

[53] L. L. Espey, “Current status of the hypothesis that mammalian ovulation is comparable to an inflammatory reaction,” Biology of Reproduction, vol. 50, pp. 233–238, 1994.
[54] R. L. Stouffer, F. Xu, and D. M. Duffy, "Molecular control of ovulation and luteinization in the primate follicle," *Frontiers in Bioscience*, vol. 12, pp. 297–307, 2007.

[55] A. Rizzo, M. T. Roscino, F. Binetti, and R. L. Sciorsci, "Roles of reactive oxygen species in female reproduction," *Reproduction in Domestic Animals*, vol. 47, pp. 344–352, 2012.

[56] N. Sugino, "Roles of reactive oxygen species in the corpus luteum," *Animal Science Journal*, vol. 77, pp. 556–565, 2006.

[57] J. C. Carlson, M. Sawada, D. L. Boone, and J. M. Staufer, "Stimulation of progesterone secretion in dispersed cells of rat corpora lutea by antioxidants," *Steroids*, vol. 60, pp. 272–276, 1995.

[58] M. Sawada and J. C. Carlson, "Intracellular regulation of progesterone secretion by the superoxide radical in the rat corpus luteum," *Endocrinology*, vol. 137, pp. 1580–1584, 1996.

[59] B. J. Gulys and L. C. Yuan, "Microperoxisomes in the late pregnancy corpus luteum of rhesus monkeys (Macaca mulatta)," *The Journal of Histochemistry and Cytochemistry*, vol. 23, pp. 359–368, 1975.

[60] Y. S. Park, S. Y. You, S. Cho et al., "Eccentric localization of catalase to protect chromosomes from oxidative damages during meiotic maturation in mouse oocytes," *Histochemistry and Cell Biology*, vol. 146, pp. 281–288, 2016.

[61] M. B. Harvey, M. Y. Arcellana-Panililo, X. Zhang, G. A. Schultz, and A. J. Watson, "Expression of genes encoding antioxidant enzymes in preimplantation mouse and cow embryos and primary bovine oviduct cultures employed for embryo coculture," *Biology of Reproduction*, vol. 53, pp. 532–540, 1995.

[62] S. L. Peterson and P. M. Stevenson, "Changes in catalase activity and concentration during ovarian development and differentiation," *Biochimica et Biophysica Acta*, vol. 1135, pp. 207–214, 1992.

[63] R. Behl and R. S. Pandey, "FSH induced stimulation of catalase activity in goat granulosa cells in vitro," *Animal Reproduction Science*, vol. 70, pp. 215–221, 2002.

[64] R. K. Parshad and S. S. Guraya, "Changes in catalase activity during follicular growth, atresia and luteinization in rat ovary," *Indian Journal of Experimental Biology*, vol. 31, pp. 109–111, 1993.

[65] J. D. Nell and M. S. Smith, "Pituitary-ovarian interrelationships in the rat," *Current Topics in Experimental Endocrinology*, vol. 2, pp. 73–106, 1974.

[66] A. C. Enders and D. M. Nelson, "Pinocytotic activity of the uterus of the rat," *The American Journal of Anatomy*, vol. 138, pp. 277–299, 1973.

[67] D. Singh and R. S. Pandey, "Changes in catalase activity and hydrogen peroxide level in rat ovary during estrous cycle and induction of catalase in rat ovary by estradiol-17 beta," *Indian Journal of Experimental Biology*, vol. 36, pp. 421–423, 1998.

[68] K. H. El-Shahat and M. Kandil, "Antioxidant capacity of follicular fluid in relation to follicular size and stage of estrous cycle in buffaloes," *Theriogenology*, vol. 77, pp. 1513–1518, 2012.

[69] G. Basini, B. Simona, S. E. Santini, and F. Grasselli, "Reactive oxygen species and anti-oxidant defences in swine follicular fluids," *Reproduction, Fertility, and Development*, vol. 20, pp. 269–274, 2008.

[70] J. E. Fortune, "Ovarian follicular growth and development in mammals," *Biography of Reproduction*, vol. 50, pp. 225–232, 1994.

[71] S. P. Klinken and P. M. Stevenson, "Changes in enzyme activities during the artificially stimulated transition from follicular to luteal cell types in rat ovary," *European Journal of Biochemistry*, vol. 81, pp. 327–332, 1977.

[72] V. H. Black and J. J. Russo, "Stereochemical analysis of the guinea pig adrenal: effects of dexamethasone and ACTH treatment with emphasis on the inner cortex," *The American Journal of Anatomy*, vol. 159, pp. 85–120, 1980.

[73] J. J. Russo and V. H. Black, "Hormone-dependent changes in peroxisomal enzyme activity in guinea pig adrenal," *The Journal of Biological Chemistry*, vol. 257, pp. 3883–3889, 1982.

[74] R. C. Tuckey, Z. Kostadinovic, and P. M. Stevenson, "Ferredoxin and cytochrome P-450scc concentrations in granulosa cells of porcine ovaries during follicular cell growth and luteinization," *Journal of Steroid Biochemistry*, vol. 31, pp. 201–205, 1988.

[75] S. G. Sligar, J. D. Lipscomb, P. G. Debrunner, and I. C. Gunsalus, "Superoxide anion production by the autoxidation of cytochrome P450cam," *Biochemical and Biophysical Research Communications*, vol. 61, pp. 290–296, 1974.

[76] R. C. Tuckey and H. Kamin, "The oxyferro complex of adrenal cytochrome P-450scx. Effect of cholesterol and intermediates on its stability and optical characteristics," *The Journal of Biological Chemistry*, vol. 257, pp. 9309–9314, 1982.

[77] J. W. Chu and T. K. Kimura, "Studies on adrenal steroid hydroxylases. Complex formation of the hydroxylase components," *The Journal of Biological Chemistry*, vol. 248, pp. 5183–5187, 1973.

[78] K. Goda, J. Chu, T. Kimura, and A. P. Schaap, "Cytochrome c enhancement of singlet molecular oxygen production by the NADPH-dependent adrenodoxin reductase-adrenodoxin system: the role of singlet oxygen in damaging adrenal mitochondrial membranes," *Biochemical and Biophysical Research Communications*, vol. 52, pp. 1300–1306, 1973.

[79] H. R. Behrman and R. F. Aten, "Evidence that hydrogen peroxide blocks hormone-sensitive cholesterol transport into mitochondria of rat luteal cells," *Endocrinology*, vol. 128, pp. 2958–2966, 1991.

[80] M. Shiotani, Y. Noda, K. Narimoto et al., "Immunohistochemical localization of superoxide dismutase in the human ovary," *Human Reproduction*, vol. 6, pp. 1349–1353, 1991.

[81] M. Laloraya, K. G. Pradeep, and M. M. Laloraya, "Changes in the levels of superoxide anion radical and superoxide dismutase during the estrous cycle of Rattus norvegicus and induction of superoxide dismutase in rat ovary by lutropin," *Biochemical and Biophysical Research Communications*, vol. 157, pp. 146–153, 1988.

[82] M. Laloraya, G. P. Kumar, and M. M. Laloraya, "Histochemical study of superoxide dismutase in the ovary of the rat during the oestrous cycle," *Journal of Reproduction and Fertility*, vol. 86, pp. 583–587, 1989.

[83] C. M. Combelles, E. A. Holick, L. J. Paolella, D. C. Walker, and Q. Wu, "Profiling of superoxide dismutase isoenzymes in compartments of the developing bovine antral follicles," *Reproduction*, vol. 139, pp. 871–881, 2010.

[84] F. Hozyen H, H. Ahmed H, G. E. Essawy, and S. I. Shalaby, "Seasonal changes in some oxidant and antioxidant
parameters during folliculogenesis in Egyptian buffalo,” *Animal Reproduction Science*, vol. 151, pp. 131–136, 2014.

[85] L. Sabatini, C. Wilson, A. Lower, T. Al-Shawaf, and J. G. Grudzinskas, “Superoxide dismutase activity in human follicular fluid after controlled ovarian hyperstimulation in women undergoing in vitro fertilization,” *Fertility and Sterility*, vol. 72, pp. 1027–1034, 1999.

[86] M. L. Sutton, R. B. Gilchrist, and J. G. Thompson, “Effects of in-vivo and in-vitro environments on the metabolism of the cumulus-oocyte complex and its influence on oocyte developmental capacity,” *Human Reproduction Update*, vol. 9, pp. 35–48, 2003.

[87] H. Tateno, N. Muto, I. Sunagawa, A. Shinjo, and T. Nakada, “Protection of porcine oocytes against cell damage caused by oxidative stress during in vitro maturation: role of superoxide dismutase activity in porcine follicular fluid,” *Biology of Reproduction*, vol. 71, pp. 1150–1157, 2004.

[88] T. Ookawara, T. Kizaki, E. Takayama et al., “Nuclear translocation of extracellular superoxide dismutase,” *Biochemical and Biophysical Research Communications*, vol. 296, pp. 54–61, 2002.

[89] F. Johnson and C. Giuliani, “Superoxide dismutases and their impact upon human health,” *Molecular Aspects of Medicine*, vol. 26, pp. 340–352, 2005.

[90] I. A. Abreu and D. E. Cabelli, “Superoxide dismutase: a review of the metal-associated mechanistic variations,” *Biochimica et Biophysica Acta*, vol. 1804, pp. 263–274, 2010.

[91] E. Nozik-Grayck, H. B. Suliman, and C. A. Piantadosi, “Extracellular superoxide dismutase,” *The International Journal of Biochemistry & Cell Biology*, vol. 37, pp. 2466–2471, 2005.

[92] M. M. Matzuk, L. Dionne, Q. Guo, T. R. Kumar, and R. M. Lebovitz, “Ovarian function in superoxide dismutase 1 and 2 knockout mice,” *Endocrinology*, vol. 139, pp. 4008–4011, 1998.

[93] P. C. Wong, D. Waggoner, J. R. Subramaniam et al., “Copper chaperone for superoxide dismutase is essential to activate mammalian CuZn superoxide dismutase,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 97, pp. 2886–2891, 2000.

[94] A. Kably Ambe, J. Ruiz Anguas, E. Carballo Mondragon, and S. Karchmer Krivitsky, “Intrafollicular levels of sexual steroids and their relation with the antioxidant enzymes on the oocyte quality in an in vitro fertilization program,” *Ginecología y Obstetricia de México*, vol. 73, pp. 19–27, 2005.

[95] P. S. LaPolt and L. S. Hong, “Inhibitory effects of superoxide dismutase and cyclic guanosine 3′,5′-monophosphate on estrogen production in cultured rat granulosa cells,” *Endocrinology*, vol. 136, pp. 5533–5539, 1995.

[96] M. Ujihara, K. Yamamoto, K. Nomura et al., “Subunit-specific sulphation of oligosaccharides relating to charge heterogeneity in porcine lutropin isoforms,” *Glycobiology*, vol. 2, pp. 225–231, 1992.

[97] S. Kawaguchi, R. Sakamoto, and K. Oudaka, “Induction of the expressions of antioxidant enzymes by luteinizing hormone in the bovine corpus luteum,” *The Journal of Reproduction and Development*, vol. 59, pp. 219–224, 2013.

[98] K. H. Al-Gubory, J. C. Huet, J. C. Pernollet, J. Martal, and A. Locatelli, “Corpus luteum derived copper, zinc-superoxide dismutase serves as a luteinizing hormone-release inhibiting factor in sheep,” *Molecular and Cellular Endocrinology*, vol. 199, pp. 1–9, 2003.

[99] A. Meister and M. E. Anderson, “Glutathione,” *Annual Review of Biochemistry*, vol. 52, pp. 711–760, 1983.

[100] B. Ketterer, B. Coles, and D. J. Meyer, “The role of glutathione in detoxication,” *Environmental Health Perspectives*, vol. 49, pp. 59–69, 1983.

[101] H. Sies, “Glutathione and its role in cellular functions,” *Free Radical Biology & Medicine*, vol. 27, pp. 916–921, 1999.

[102] T. Kaneko, Y. Iuchi, S. Kawachiya et al., “Alteration of glutathione reductase expression in the female reproductive organs during the estrous cycle,” *Biology of Reproduction*, vol. 65, pp. 1410–1416, 2001.

[103] U. Luderer, T. J. Kavanagh, C. C. White, and E. M. Faustman, “Gonadotropin regulation of glutathione synthesis in the rat ovary,” *Reproductive Toxicology*, vol. 15, pp. 495–504, 2001.

[104] S. Y. Lee, J. Y. Lee, S. J. Oh, H. C. Kim, and S. K. Kim, “Expression of hepatic and ovarian antioxidant enzymes during estrous cycle in rats,” *Toxicology Letters*, vol. 212, pp. 329–336, 2012.

[105] C. S. Gardiner and D. J. Reed, “Status of glutathione during oxidant-induced oxidative stress in the preimplantation mouse embryo,” *Biology of Reproduction*, vol. 51, pp. 1307–1314, 1994.

[106] E. C. Curnow, J. Ryan, D. Saunders, and E. S. Hayes, “Bovine in vitro oocyte maturation as a model for manipulation of the gamma-glutamyl cycle and intraoocyte glutathione,” *Reproduction, Fertility, and Development*, vol. 20, pp. 579–588, 2008.

[107] M. C. Sanchez, C. A. Sedo, V. L. Julianelli et al., “Dermatan sulfate synergizes with heparin in murine sperm chromatin decondensation,” *Systems Biology in Reproductive Medicine*, vol. 59, pp. 82–90, 2013.

[108] D. G. de Matos, C. C. Furnus, D. F. Moses, and H. Baldassarre, “Effect of cysteamine on glutathione level and developmental capacity of bovine oocyte matured in vitro,” *Molecular Reproduction and Development*, vol. 42, pp. 432–436, 1995.

[109] M. Takahashi, T. Nagai, S. Hamano, M. Kuwayama, N. Okamura, and A. Okano, “Effect of thiol compounds on in vitro development and intracellular glutathione content of bovine embryos,” *Biology of Reproduction*, vol. 49, pp. 228–232, 1993.

[110] T. Paszkowski, A. I. Traub, S. Y. Robinson, and D. McMaster, “Selenium dependent glutathione peroxidase activity in human follicular fluid,” *Clinica Chimica Acta*, vol. 236, pp. 173–180, 1995.

[111] N. Clague, M. Sevcik, G. Stuart, M. Brannstrom, P. O. Janson, and J. F. Jarrell, “The effect of estrous cycle and buthionine sulfoximine on glutathione release from the in vitro perfused rat ovary,” *Reproductive Toxicology*, vol. 6, pp. 533–539, 1992.

[112] N. Maedomari, K. Kikuchi, M. Ozawa et al., “Cytoplasmic glutathione regulated by cumulus cells during porcine oocyte maturation affects fertilization and embryonic development in vitro,” *Theriogenology*, vol. 67, pp. 983–993, 2007.

[113] E. J. Schoevers, B. Colenbrander, and B. A. Roelen, “Developmental stage of the oocyte during antral follicle growth and cumulus investment determines in vitro embryo development of sow oocytes,” *Theriogenology*, vol. 67, pp. 1108–1122, 2007.
[114] A. M. Luciano, V. Lodde, M. S. Beretta, S. Colleoni, A. Lauria, and S. Modina, "Developmental capability of denuded bovine oocyte in a co-culture system with intact cumulus-oocyte complexes: role of cumulus cells, cyclic adenosine 3′,5′-monophosphate, and glutathione," Molecular Reproduction and Development, vol. 71, pp. 389–397, 2005.

[115] A. M. Luciano, G. Goudet, F. Perazzoli, C. Lahuec, and N. Gerard, "Glutathione content and glutathione peroxidase expression in in vivo and in vitro matured equine oocytes," Molecular Reproduction and Development, vol. 73, pp. 658–666, 2006.

[116] M. Ozawa, T. Nagai, T. Somfai et al., "Cumulus cell-enclosed oocytes acquire a capacity to synthesize GSH by FSH stimulation during in vitro maturation in pigs," Journal of Cellular Physiology, vol. 222, pp. 294–301, 2010.

[117] M. L. Sutton-McDowall, M. Purdey, H. M. Brown et al., "Redox and anti-oxidant state within cattle oocytes following in vitro maturation with bone morphogenetic protein 15 and follicle stimulating hormone," Molecular Reproduction and Development, vol. 82, pp. 281–294, 2015.

[118] T. S. Hussein, J. G. Thompson, and R. B. Gilchrist, "Oocyte-secreted factors enhance oocyte developmental competence," Developmental Biology, vol. 296, pp. 514–521, 2006.

[119] J. L. Crawford and K. P. McNatty, "The ratio of growth differentiation factor 9: bone morphogenetic protein 15 mRNA expression is tightly co-regulated and differs between species over a wide range of ovulation rates," Molecular and Cellular Endocrinology, vol. 348, pp. 339–343, 2012.

[120] Y. S. Ho, J. L. Magenat, R. T. Bronson et al., "Mice deficient in cellular glutathione peroxidase develop normally and show no increased sensitivity to hyperoxia," The Journal of Biological Chemistry, vol. 272, pp. 16644–16651, 1997.

[121] L. J. Yant, Q. Ran, L. Rao et al., "The selenoprotein GPX4 is essential for mouse development and protects from radiation and oxidative damage insults," Free Radical Biology & Medicine, vol. 34, pp. 496–502, 2003.

[122] M. Schneider, H. Forster, A. Boersma et al., "Mitochondrial glutathione peroxidase 4 disruption causes male infertility," The FASEB Journal, vol. 23, pp. 3233–3242, 2009.

[123] M. Conrad, S. G. Moreno, F. Sinowatz et al., "The nuclear form of phospholipid hydroperoxide glutathione peroxidase is a protein thiol peroxidase contributing to sperm chromatin stability," Molecular and Cellular Biology, vol. 25, pp. 7637–7644, 2005.

[124] W. Pretsch, "Glutathione reductase activity deficiency in homozygous Grx1/Neu mice does not cause haemolytic anaemia," Genetical Research, vol. 73, pp. 1–5, 1999.

[125] L. K. Rogers, C. M. Bates, S. E. Welty, and C. V. Smith, "Diquat induces renal proximal tubule injury in glutathione reductase-deficient mice," Toxicology and Applied Pharmacology, vol. 217, pp. 289–298, 2006.

[126] L. K. Rogers, T. Tamura, B. J. Rogers, S. E. Welty, T. N. Hansen, and C. V. Smith, "Analyses of glutathione reductase hypomorphic mice indicate a genetic knockout," Toxicological Sciences, vol. 82, pp. 367–373, 2004.

[127] T. R. Kumar, A. L. Wiseman, G. Kala, S. V. Kala, M. M. Matzuk, and M. W. Lieberman, "Reproductive defects in gamma-glutamyl transpeptidase-deficient mice," Endocrinology, vol. 141, pp. 4270–4277, 2000.

[128] M. W. Lieberman, A. L. Wiseman, Z. Z. Shi et al., "Growth retardation and cysteine deficiency in gamma-glutamyl transpeptidase-deficient mice," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, pp. 7923–7926, 1996.

[129] Y. Will, K. A. Fischer, R. A. Horton et al., "Gamma-glutamyl transpeptidase-deficient knockout mice as a model to study the relationship between glutathione status, mitochondrial function, and cellular function," Hepatology, vol. 32, pp. 740–749, 2000.

[130] G. Giordano, C. C. White, L. A. McConnachie, C. Fernandez, T. J. Kavanagh, and L. G. Costa, "Neurotoxicity of domoic acid in cerebellar granule neurons in a genetic model of glutathione deficiency," Molecular Pharmacology, vol. 70, pp. 2116–2126, 2006.

[131] Y. Yang, M. Z. Dieter, Y. Chen, H. G. Shertzter, and T. P. Dalton, "Initial characterization of the glutamate-cysteine ligase modifier subunit Gclm(−/−) knockout mouse. Novel model system for a severely compromised oxidative stress response," The Journal of Biological Chemistry, vol. 277, pp. 49446–49452, 2002.

[132] T. P. Dalton, M. Z. Dieter, Y. Yang, H. G. Shertzter, and D. W. Nebert, "Knockout of the mouse glutamate cysteine ligase catalytic subunit (Gclc) gene: embryonic lethal when homozygous, and proposed model for moderate glutathione deficiency when heterozygous," Biochemical and Biophysical Research Communications, pp. 324–329, 2000.

[133] Z. Z. Shi, J. Osei-Frimpong, G. Kala et al., "Glutathione synthesis is essential for mouse development but not for cell growth in culture," Proceedings of the National Academy of Sciences of the United States of America, vol. 97, pp. 5101–5106, 2000.

[134] B. N. Nakamura, T. J. Fielder, Y. D. Hoang et al., "Lack of maternal glutamate cysteine ligase modifier subunit (Gclm) decreases oocyte glutathione concentrations and disrupts preimplantation development in mice," Endocrinology, vol. 152, pp. 2806–2815, 2011.

[135] S. G. Lopez and U. Luderer, "Effects of cyclophosphamide and buthionine sulfoximine on ovarian glutathione and apoptosis," Free Radical Biology & Medicine, vol. 36, pp. 1366–1377, 2004.

[136] S. Y. Chun, H. Billig, J. L. Tilly, I. Furuta, A. Tsafiriri, and A. J. Hsueh, "Gonadotropin suppression of apoptosis in cultured preovulatory follicles: mediatory role of endogenous insulin-like growth factor I," Endocrinology, vol. 135, pp. 1845–1853, 1994.

[137] S. Y. Chun, K. M. Eisenhauer, S. Minami, H. Billig, E. Perlas, and A. J. Hsueh, "Hormonal regulation of apoptosis in early antral follicles: follicle-stimulating hormone as a major survival factor," Endocrinology, vol. 137, pp. 1447–1456, 1996.

[138] M. Tsai-Turton and U. Luderer, "Opposing effects of glutathione depletion and follicle-stimulating hormone on reactive oxygen species and apoptosis in cultured preovulatory rat follicles," Endocrinology, vol. 147, pp. 1224–1236, 2006.

[139] Y. D. Hoang, B. N. Nakamura, and U. Luderer, "Follicle-stimulating hormone and estradiol interact to stimulate glutathione synthesis in rat ovarian follicles and granulosa cells," Biology of Reproduction, vol. 81, pp. 636–646, 2009.

[140] J. L. Tilly and K. I. Tilly, "Inhibitors of oxidative stress mimic the ability of follicle-stimulating hormone to suppress apoptosis in cultured rat ovarian follicles," Endocrinology, vol. 136, pp. 242–252, 1995.

[141] E. D. Dubinskaya, A. S. Gasparov, T. A. Fedorova, and N. V. Lapteva, "Role of the genetic factors, detoxication systems
and oxidative stress in the pathogenesis of endometriosis and infertility (review),” *Vestnik Rossiskoi Akademii Meditsinskikh Nauk*, vol. 8, pp. 14–19, 2013.

[142] J. J. Tarin, “Potential effects of age-associated oxidative stress on mammalian oocytes/embryos,” *Molecular Human Reproduction*, vol. 2, pp. 717–724, 1996.

[143] P. Guerin, S. El Mouatassim, and Y. Menezo, “Oxidative stress and protection against reactive oxygen species in the pre-implantation embryo and its surroundings,” *Human Reproduction Update*, vol. 7, pp. 175–189, 2001.

[144] T. Sabuncu, H. Vural, M. Harma, and M. Harma, “Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease,” *Clinical Biochemistry*, vol. 34, pp. 407–413, 2001.

[145] E. H. Ruder, T. J. Hartman, J. Blumberg, and M. B. Goldman, “Oxidative stress and antioxidants: exposure and impact on female fertility,” *Human Reproduction Update*, vol. 14, pp. 345–357, 2008.

[146] L. Qin, W. Xu, X. Li et al., “Differential expression profile of immunological cytokines in local ovary in patients with polycystic ovarian syndrome: analysis by flow cytometry,” *European Journal of Obstetrics, Gynecology, and Reproductive Biology*, vol. 197, pp. 136–141, 2016.

[147] L. Chen, W. M. Xu, and D. Zhang, “Association of abdominal obesity, insulin resistance, and oxidative stress in adipose tissue in women with polycystic ovary syndrome,” *Fertility and Sterility*, vol. 102, pp. 1167–1174.e1164, 2014.

[148] T. Zuo, M. Zhu, and W. Xu, “Roles of oxidative stress in polycystic ovary syndrome and cancers,” *Oxidative Medicine and Cellulare Longevity*, vol. 2016, Article ID 8589318, 14 pages, 2016.

[149] B. Fauser, “Consensus on diagnostic criteria and longterm health risks related to polycystic ovary syndrome,” in *ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group*, Vol. 8, pp. 19–25, Fertil Steril, Rotterdam, 2004.

[150] V. M. Victor, M. Rocha, C. Banuls et al., “Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 96, pp. 3115–3122, 2011.

[151] D. Zhang, W. Y. Luo, H. Liao, C. F. Wang, and Y. Sun, “The effects of oxidative stress to PCOS,” *Sichuan Da Xue Xue Bao Yi Xue Ban*, vol. 39, pp. 421–423, 2008.

[152] F. Gonzalez, N. S. Rote, J. Minium, and J. P. Kirwan, “Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome,” *The Journal of Clinical Endocrinology and Metabolism*, vol. 91, pp. 336–340, 2006.

[153] ASRM, “Definition of ‘infertility’,” *Fertility and Sterility*, vol. 82, Supplement 1, article S206, 2004.

[154] A. DeCherney, L. Nathan, M. Eskandari, and M. Cadieux, *Current Obstetric & Gynecologic Diagnosis & Treatment*, pp. 979–990, 2003.

[155] G. Polak, M. Koziol-Montewka, R. Tarkowski, and J. Kotarski, “Peritoneal fluid and plasma 4-hydroxynonenal and malondialdehyde concentrations in infertile women,” *Ginekologia Polska*, vol. 72, pp. 1316–1320, 2001.

[156] G. Polak, R. Rola, M. Gogacz, M. Koziol-Montewka, and J. Kotarski, “Malondialdehyde and total antioxidant status in the peritoneal fluid of infertile women,” *Ginekologia Polska*, vol. 70, pp. 135–140, 1999.

[157] S. Gupta, N. Surti, L. Metterle, A. Chandra, and A. Agarwal, “Antioxidants and female reproductive pathologies,” *Archives of Medical Science Special Issues*, vol. 5, pp. 151–173, 2009.

[158] Y. Wang, R. Sharma, T. Falcone, J. Goldberg, and A. Agarwal, “Importance of reactive oxygen species in the peritoneal fluid of women with endometriosis or idiopathic infertility,” *Fertility and Sterility*, vol. 68, pp. 826–830, 1997.

[159] R. Sharma, K. R. Biedenharn, J. M. Fedor, and A. Agarwal, “Lifestyle factors and reproductive health: taking control of your fertility,” *Reproductive Biology and Endocrinology*, vol. 11, p. 66, 2013.

[160] S. K. Chaube, P. V. Prasad, S. C. Thakur, and T. G. Shrivastav, “Hydrogen peroxide modulates meiotic cell cycle and induces morphological features characteristic of apoptosis in rat oocytes cultured in vitro,” *Apoptosis*, vol. 10, pp. 863–874, 2005.

[161] A. Tripathi, K. V. PremKumar, A. N. Pandey et al., “Melatonin protects against clophene citrate-induced generation of hydrogen peroxide and morphological apoptotic changes in rat eggs,” *European Journal of Pharmacology*, vol. 667, pp. 419–424, 2011.

[162] A. Tripathi, T. G. Shrivastav, and S. K. Chaube, “An increase of granulosa cell apoptosis mediates aqueous neem (Azadirachta Indica) leaf extract-induced oocyte apoptosis in rat,” *International Journal of Applied and Basic Medical Research*, vol. 3, pp. 27–36, 2013.

[163] S. K. Chaube, T. G. Shrivastav, M. Tiwari, S. Prasad, A. Tripathi, and A. K. Pandey, “Neem (Azadirachta Indica L.) leaf extract deteriorates oocyte quality by inducing ROS-mediated apoptosis in mammals,” *SpringerPlus*, vol. 3, p. 464, 2014.

[164] A. Agarwal, T. M. Said, M. A. Bedaiwy, J. Banerjee, and J. G. Alvarez, “Oxidative stress in an assisted reproductive techniques setting,” *Fertility and Sterility*, vol. 86, pp. 503–512, 2006.

[165] A. Iborra, J. R. Palacio, and P. Martinez, “Oxidative stress and immune response in the infertile woman,” *Chemical Immunology and Allergy*, vol. 88, pp. 150–162, 2005.

[166] M. C. Carbone, C. Tatone, S. Delle Monache et al., “Antioxidant enzymatic defences in human follicular fluid: characterization and age-dependent changes,” *Molecular Human Reproduction*, vol. 9, pp. 639–643, 2003.

[167] J. Lim and U. Luderer, “Oxidative damage increases and antioxidant gene expression decreases with aging in the mouse ovary,” *Biologie of Reproduction*, vol. 84, pp. 775–782, 2011.

[168] H. Y. Lian, Y. Gao, G. Z. Jiao et al., “Antioxidant supplementation overcomes the deleterious effects of maternal restraint stress-induced oxidative stress on mouse oocytes,” *Reproduction*, vol. 146, pp. 559–568, 2013.

[169] H. Tamura, A. Takasaki, I. Miwa et al., “Oxidative stress impairs oocyte quality and melatonin protects oocytes from free radical damage and improves fertilization rate,” *Journal of Pinical Research*, vol. 44, pp. 280–287, 2008.

[170] O. G. Eryilmaz, A. Devran, E. Sarikaya, F. N. Aksakal, L. Mollamahmutoglu, and N. Cicek, “Melatonin improves the oocyte and the embryo in IVF patients with sleep disturbances, but does not improve the sleeping problems,” *Journal of Assisted Reproduction and Genetics*, vol. 28, pp. 815–820, 2011.
[171] A. S. Batioglu, U. Sahin, B. Gurlek, N. Ozturk, and E. Unsal, “The efficacy of melatonin administration on oocyte quality,” Gynecological Endocrinology, vol. 28, pp. 91–93, 2012.

[172] M. Liu, Y. Yin, X. Ye et al., “Resveratrol protects against age-associated infertility in mice,” Human Reproduction, vol. 28, pp. 707–717, 2013.

[173] J. Mier-Cabrera, T. Aburto-Soto, S. Burrola-Mendez et al., “Women with endometriosis improved their peripheral antioxidant markers after the application of a high antioxidant diet,” Reproductive Biology and Endocrinology, vol. 7, p. 54, 2009.

[174] J. Mier-Cabrera, M. Genera-Garcia, J. De la Jara-Diaz, O. Perichart-Perera, F. Vadillo-Ortega, and C. Hernandez-Guerrero, “Effect of vitamins C and E supplementation on peripheral oxidative stress markers and pregnancy rate in women with endometriosis,” International Journal of Gynaecology and Obstetrics, vol. 100, pp. 252–256, 2008.

[175] I. A. Cotgreave, “N-Acetylcysteine: pharmacological considerations and experimental and clinical applications,” Advances in Pharmacology, vol. 38, pp. 205–227, 1997.

[176] G. S. Kelly, “Clinical applications of N-acetylcysteine,” Alternative Medicine Review, vol. 3, pp. 114–127, 1998.

[177] A. F. Amin, O. M. Shaaban, and M. A. Bediawy, “N-Acetyl cysteine for treatment of recurrent unexplained pregnancy loss,” Reproductive Biomedicine Online, vol. 17, pp. 722–726, 2008.

[178] A. Rumbold, L. Duley, C. Crowther, and R. Haslam, “Antioxidants for preventing pre-eclampsia,” Cochrane Database of Systematic Reviews, vol. 4, article CD004227, 2005.

[179] L. Poston, A. L. Briley, P. T. Seed, F. J. Kelly, A. H. Shennan, and Vitamins in Pre-eclampsia (VIP) Trial Consortium, “Vitamin C and vitamin E in pregnant women at risk for pre-eclampsia (VIP trial): randomised placebo-controlled trial,” Lancet, vol. 367, pp. 1145–1154, 2006.

[180] J. M. Roberts, L. Myatt, C. Y. Spong et al., “Vitamins C and E to prevent complications of pregnancy-associated hypertension,” The New England Journal of Medicine, vol. 362, pp. 1282–1291, 2010.

[181] H. Xu, R. Perez-Cuevas, X. Xiong et al., “An international trial of antioxidants in the prevention of preeclampsia (INTAPP),” American Journal of Obstetrics and Gynecology, vol. 202, pp. 239.e1–239.e10, 2010.

[182] G. S. Aseervatham, T. Sivasudha, R. Jeyadevi, and D. Arul Ananth, “Environmental factors and unhealthy lifestyle influence oxidative stress in humans—an overview,” Environmental Science and Pollution Research International, vol. 20, pp. 4356–4369, 2013.